Thromb Haemost 1966; 16(01/02): 243-256
DOI: 10.1055/s-0038-1655641
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Hemorrhagic Syndrome in Dogs Induced by Intravenous Thrombin

A Girolami*
1   Clotting Mechanisms Section, Sloan-Kettering Institute for Cancer Research and Cornell University Medical College, New York, New York
,
E. E Cliffton**
1   Clotting Mechanisms Section, Sloan-Kettering Institute for Cancer Research and Cornell University Medical College, New York, New York
,
D Agostino***
1   Clotting Mechanisms Section, Sloan-Kettering Institute for Cancer Research and Cornell University Medical College, New York, New York
› Institutsangaben

This work was supported by grant # C 3817 of the N. C. I., # H 2867 of the N. H. I. and Institutional funds.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
26. Juni 2018 (online)

Preview

Summary

The intravenous administration of thrombin (70 N. I. H. u/kg) caused in the dog a decrease in platelets, factor V, factor VIII and fibrinogen, a prolongation of glass and silicone clotting times, prothrombin and partial thromboplastin times, decreased prothrombin consumption and defective thromboplastin generation. This resulted in a generalized bleeding syndrome. Increased fibrinolysis occurred after an initial phase of inhibition of fibrinolysis. It is suggested that this hemorrhagic syndrome is similar to some conditions observed clinically.

* Visiting Research Fellow, Sloan-Kettering Institute for Cancer Research. Permanent Address: Institute of “Semeiotica Medica” (Head: Prof. M. Austoni), University of Padua Medical School, Padua, Italy.


** Associate Member, Sloan-Kettering Institute for Cancer Research.


*** Research Associate, Sloan-Kettering Institute for Cancer Research.